Mark Haden
Corporate Officer/Principal chez CLEARMIND MEDICINE INC.
Fortune : 150 $ au 31/05/2024
Profil
Mark Haden is currently the Vice President of Business Development at Clearmind Medicine, Inc. He previously worked as the Director of Clinical Trials at Psygen Labs, Inc. from 2021 to 2022 and as the Executive Director at Multidisciplinary Association for Psychedelic Studies Canada from 2017 to 2021.
Haden received his undergraduate and graduate degrees from the University of British Columbia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CLEARMIND MEDICINE INC.
0,00% | 31/10/2023 | 133 ( 0,00% ) | 150 $ | 31/05/2024 |
Postes actifs de Mark Haden
| Sociétés | Poste | Début |
|---|---|---|
| CLEARMIND MEDICINE INC. | Corporate Officer/Principal | 01/07/2021 |
Anciens postes connus de Mark Haden
| Sociétés | Poste | Fin |
|---|---|---|
Psygen Labs, Inc.
 Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Corporate Officer/Principal | 01/03/2022 |
Formation de Mark Haden
| University of British Columbia | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CLEARMIND MEDICINE INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Health Technology |
